| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | MMP9, MMP-9, Matrix metalloproteinase 9, CLG4B, 82kDa matrix metalloproteinase-9, Collagenease type 4 beta, GELB, Macrophage gelatinase, MANDP2, Type V collagenase, 92 kDa gelatinase, 92 kDa type IV collagenase, Gelatinase B |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Fusion protein amino acids 1-708 (full length) of rat MMP9 |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
Matrix metalloproteinase 9 (MMP9) is an extracellular endopeptidase involved in the degradation of the extracellular matrix (ECM). In the central nervous system, MMP9 regulates synaptic remodeling, neuroinflammation, and blood-brain barrier permeability.
Elevated MMP9 activity has been observed in neurodegenerative diseases such as Alzheimer’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). MMP9 contributes to neuronal injury by promoting ECM breakdown, facilitating leukocyte infiltration, and activating pro-inflammatory cytokines.
MMP9 is synthesized as a latent proenzyme and requires proteolytic cleavage for activation. Its expression is tightly regulated at the transcriptional level and by endogenous inhibitors such as TIMPs (tissue inhibitors of metalloproteinases).
Targeting MMP9 activity offers therapeutic potential for preserving blood-brain barrier integrity, reducing neuroinflammation, and limiting tissue damage in neurodegenerative conditions.
1 µg/ml of SMC-396 was sufficient for detection of MMP9 in 20 µg of COS-1 cells (lysate) transfected with human MMP9 by colorimetric immunoblot analysis using goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-396D — Size: 100 ug: MMP9 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396D, RRID: AB_11232604)
- SMC-396D-A390 — Size: 100 ug: MMP9 Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396D-A390, RRID: AB_2700890)
- SMC-396D-A488 — Size: 100 ug: MMP9 Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396D-A488, RRID: AB_2700891)
- SMC-396D-A594 — Size: 100 ug: MMP9 Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396D-A594, RRID: AB_2700893)
- SMC-396D-APC — Size: 100 ug: MMP9 Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396D-APC, RRID: AB_2700899)
- SMC-396D-BI — Size: 100 ug: MMP9 Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396D-BI, RRID: AB_2700900)
- SMC-396D-FITC — Size: 100 ug: MMP9 Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396D-FITC, RRID: AB_2700901)
- SMC-396D-HRP — Size: 100 ug: MMP9 Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396D-HRP, RRID: AB_2700902)
- SMC-396D-PCP — Size: 100 ug: MMP9 Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396D-PCP, RRID: AB_2700904)
- SMC-396D-RPE — Size: 100 ug: MMP9 Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396D-RPE, RRID: AB_2700905)
- SMC-396S — Size: 12 ug: MMP9 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-396S, RRID: AB_11232604)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Coussens L.M., et al. (2002) Science 295: 2387-2391.
3. Sternlicht M.D., et al. (1999) Cell 98: 137-146.
4. Vu T.H., et al. (1998) Cell 93: 411-422.
5. Nagase H., et al. (1990) Biochemistry 29: 5783-5789.
